Meeting goals Provide participants – Current status regarding Classification Diagnosis Management – Update on the latest developments in neuroendocrine tumors (NETs) Address key open questions & controversies in the management of NETs Present characteristic clinical cases

ENETS GUIDELINES Latest 2015 updated

ENETS Consensus NamingConsistencyTissue of origin DiagnosingNature of diseaseWHO classification GradingBiological behaviorProliferative fraction * StagingDisease extensionTNM staging

TNM classification

Targeting NETs – Data from Phase III studies Somatostatin receptors highly expressed by NETs –Targeting SSTRs can provide besides symptom also disease control New potential targets : –mTOR, PI3K, VEGF inhibitors –Other antiangiogenic agents Targeted & combination treatments evolving Long acting - somatostatin analogs Sunitinib Everolimus Bevacizumab

Multidisciplinary team achievements Improved 5 year survival – UK colorectal & esophageal cancer Improved 2 year survival – UK neck & head cancer Improved 7 year relative survival – Sweden breast cancer

Gastroenterologists Geneticists Endocrinologists Surgeons Research nurses Oncologists Radiologists – Nuclear Medicine Pathologists Target audience – Multidisciplinary team (MDT) NET patient

Advances of MDT management of NETs Accurate diagnosis and staging Evaluation of performance status and quality of life Consensus regarding patient’s care plan Cohesive delivery of support, therapy and information on prognosis Continous reassesment, discussion, and peer review of individualized care plan